The Centres for Medicare and Medicaid Services on Friday said that it did not move forward with a proposal put forward by the ...

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out a key provision that would have expanded coverage for weight-loss drugs. In response, Eli Lilly stock ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce weight.

The Trump administration said Friday that Medicare and Medicaid won’t expand coverage of popular anti-obesity drugs, ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...